DRUG FOR INFLAMMATORY BOWEL DISEASE

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20130004516A1
SERIAL NO

13582179

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Anti-CD81 antibody displays not only a remission induction effect, but also a long-term remission maintenance effect on inflammatory bowel disease when administered in a single dose, and is therefore effective as a drug for maintaining remission from inflammatory bowel disease. Moreover, anti-CD81 antibody is effective as a drug for the prevention, amelioration and treatment of inflammatory bowel disease because it has preventive, therapeutic and ameliorating effects on refractory inflammatory bowel disease.

First Claim

See full text

Other Claims data not available

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SUMITOMO DAINIPPON PHARMA CO LTDOSAKA-SHI OSAKA 541-8524

International Classification(s)

loading....
  • 2011 Application Filing Year
  • A61K Class
  • 10915 Applications Filed
  • 8360 Patents Issued To-Date
  • 76.60 % Issued To-Date

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Watanabe, Takamasa Osaka-shi, JP 5 12

Cited Art Landscape

Load Citation

Patent Citation Ranking

  • 1 Citation Count
  • A61K Class
  • 14.18 % this patent is cited more than
  • 12 Age
Citation count rangeNumber of patents cited in rangeNumber of patents cited in various citation count ranges93340159383591527830328862201 - 1011 - 2021 - 3031 - 4041 - 5051 - 6061 - 7071 - 8081 - 9091 - 100100 +025050075010001250150017502000225025002750300032503500375040004250

Forward Cite Landscape

Load Citation